[{"address1": "4546 El Camino Real", "address2": "Suite B1", "city": "Los Altos", "state": "CA", "zip": "94022", "country": "United States", "phone": "650 284 4433", "fax": "650 397 4433", "website": "https://renovorx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ramtin  Agah M.D.", "age": 58, "title": "Founder, Chairman of Board & Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 332894, "exercisedValue": 0, "unexercisedValue": 173000}, {"maxAge": 1, "name": "Mr. Shaun R. Bagai", "age": 47, "title": "CEO, Secretary & Director", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 589376, "exercisedValue": 0, "unexercisedValue": 304200}, {"maxAge": 1, "name": "Mr. Robert  Strasser", "title": "Vice President of Operations and R&D", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ronald B. Kocak CPA, CGMA", "age": 67, "title": "VP, Controller & Principal Accounting Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leesa  Gentry", "age": 54, "title": "Chief Clinical Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Witt", "title": "Senior VP and Head of Corporate Strategy & Partnerships", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.03, "open": 1.01, "dayLow": 1.01, "dayHigh": 1.09, "regularMarketPreviousClose": 1.03, "regularMarketOpen": 1.01, "regularMarketDayLow": 1.01, "regularMarketDayHigh": 1.09, "beta": 1.094, "forwardPE": -2.2608695, "volume": 296377, "regularMarketVolume": 296377, "averageVolume": 141549, "averageVolume10days": 322670, "averageDailyVolume10Day": 322670, "bid": 0.7704, "ask": 1.33, "bidSize": 200, "askSize": 200, "marketCap": 36987912, "fiftyTwoWeekLow": 0.774, "fiftyTwoWeekHigh": 1.86, "fiftyDayAverage": 1.32088, "twoHundredDayAverage": 1.183315, "currency": "USD", "enterpriseValue": 15398393, "floatShares": 23545314, "sharesOutstanding": 35565300, "sharesShort": 128115, "sharesShortPriorMonth": 115525, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0053, "heldPercentInsiders": 0.01286, "heldPercentInstitutions": 0.02701, "shortRatio": 1.21, "shortPercentOfFloat": 0.0054, "impliedSharesOutstanding": 35565300, "bookValue": 0.295, "priceToBook": 3.5254238, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -9163000, "trailingEps": -0.58, "forwardEps": -0.41, "52WeekChange": -0.2536232, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RNXT", "underlyingSymbol": "RNXT", "shortName": "RenovoRx, Inc.", "longName": "RenovoRx, Inc.", "firstTradeDateEpochUtc": 1629984600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "6babfc24-dc5c-3de1-bf9d-2ec73346783e", "messageBoardId": "finmb_236111504", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.04, "targetHighPrice": 9.0, "targetLowPrice": 3.5, "targetMeanPrice": 5.5, "targetMedianPrice": 4.0, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 9563000, "totalCashPerShare": 0.398, "quickRatio": 5.397, "currentRatio": 5.661, "returnOnAssets": -0.93311995, "returnOnEquity": -2.58952, "freeCashflow": -5186875, "operatingCashflow": -8748000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]